anti-c-Met CAR T-cell therapy (Abramson Cancer Center)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-c-Met CAR T-cell therapy (Abramson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionHepatocyte growth factor receptor modulators

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbramson Cancer Center of the University of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesAbramson Cancer Center of the University of Pennsylvania

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A